MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
Rhea-AI Summary
MeiraGTx (Nasdaq: MGTX) priced an underwritten offering of 11,111,111 ordinary shares at $9.00 per share for gross proceeds of approximately $100 million. All shares are being sold by the company; the offering is expected to close on or about April 17, 2026.
The company said net proceeds, together with existing cash, are expected to fund operations and potential commercial launches of bota-vec and AAV-hAQP1 into the second half of 2028. BofA Securities and Goldman Sachs are joint bookrunners; Raymond James is co-manager.
Positive
- Gross proceeds of $100 million
- All offered shares sold by the company (direct capital raise)
- Proceeds expected to fund operations into H2 2028
- BofA and Goldman Sachs as joint bookrunners
Negative
- Issuance of 11,111,111 shares may dilute existing shareholders
- Underwriting discounts and offering expenses will reduce net proceeds
- Use of proceeds extends cash runway but not guaranteed commercial approvals
News Market Reaction – MGTX
In the Apr 16 session, MGTX declined 15.73%, reflecting a significant negative market reaction. Argus tracked a trough of -27.8% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Equity offering | Negative | -8.5% | Underwritten share offering led by Sanofi raising $50M at $4.00 per share. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The last recorded equity offering was followed by a clearly negative price reaction, suggesting past financings have pressured the stock.
Recent news shows MGTX advancing late-stage gene therapy programs and using equity offerings to fund development. A prior offering on Aug 12, 2024 raised $50M and was followed by a -8.47% move. Since late 2025, the company has reported significant licensing revenue, cash burn, and strategic partnerships. Today’s $100M offering extends funding toward potential commercial launches, continuing the pattern of external capital raises to support its pipeline.
Key Terms
underwritten offering financial
prospectus supplement regulatory
registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of
The Company believes that the net proceeds from this offering, together with its existing cash and cash equivalents, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements, including potential commercial launches of bota-vec for the treatment of X-linked retinitis pigmentosa and AAV-hAQP1 for the treatment of radiation-induced xerostomia, in each case if approved, into the second half of 2028.
BofA Securities and Goldman Sachs & Co. LLC are acting as joint book-running managers and Raymond James is acting as co-manager for the offering. The offering is expected to close on or about April 17, 2026, subject to customary closing conditions.
The ordinary shares are being offered by MeiraGTx pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) on December 21, 2023 and declared effective by the SEC on December 29, 2023. This offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC and will be available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may also be obtained by contacting: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina, 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, Telephone: (866) 471-2526 or via email: prospectus-ny@ny.email.gs.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the sufficiency of the proceeds from this offering and the Company’s cash and cash equivalents to fund operations, anticipated gross proceeds from this offering and anticipated timing for closing of the offering, as well as statements that include the words “expect,” “will,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “could,” “should,” “would,” “continue,” “anticipate,” “eligible” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks and uncertainties associated with the completion of the offering on the anticipated terms or at all, market conditions, satisfaction of customary closing conditions related to the offering and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Contacts
Investors:
MeiraGTx
Investors@meiragtx.com
or
Media:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
